SCHEMBL4594523

SCHEMBL4594523

CCCCCCCCCCCCCCCCCCOC(OCCCCCCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.56
THRB P10828 2/20 0.47
TSHR P16473 1/20 0.47
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 1/20 0.42
USP2 O75604 1/20 0.41
LPAR3 Q9UBY5 7/20 0.41
LPAR1 Q92633 6/20 0.41
LPAR2 Q9HBW0 3/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18240005 1.00 DNM1 (0.56) DNM1THRBTSHRMEN1HTT
SCHEMBL7778179 1.00 DNM1 (0.56) DNM1THRBTSHRMEN1HTT
SCHEMBL11101061 1.00 DNM1 (0.56) DNM1THRBTSHRMEN1HTT
SCHEMBL6180238 1.00 DNM1 (0.56) DNM1THRBTSHRMEN1HTT
SCHEMBL3260445 0.97 DNM1 (0.52) DNM1THRBTSHRMEN1HTT
SCHEMBL21540429 0.88 DNM1 (0.47) DNM1THRBTSHRMEN1HTT
SCHEMBL338812 0.88 ADRB2 (0.45) DNM1THRBTSHRCA1CA2
SCHEMBL28722243 0.81 DNM1 (0.45) DNM1THRBTSHRMEN1HTT
SCHEMBL11259010 0.81 DNM1 (0.45) DNM1THRBTSHRMEN1HTT
SCHEMBL23561835 0.80 DNM1 (0.54) DNM1THRBTSHRMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113710723-B Use of functionalized alpha-angelicalactone 汉高股份有限及两合公司 2024-06-18 CN disclosed
US-11697643-B2 Use of functionalized alpha-angelica lactones HENKEL AG & CO. KGAA (DE) 2023-07-11 US disclosed
EP-3725784-B1 A PROCESS FOR THE CHAIN GROWTH POLYMERIZATION OF FUNCTIONALIZED ALPHA-ANGELICA LACTONE MONOMERS HENKEL AG & CO KGAA (DE) 2022-06-29 EP disclosed
EP-3725820-B1 USE OF FUNCTIONALIZED ALPHA-ANGELICA LACTONES HENKEL AG & CO KGAA (DE) 2022-04-06 EP disclosed
US-20220033370-A1 FUNCTIONALIZED A- ANGELICA LACTONE MONOMERS AND POLYMERS OBTAINED THEREFROM HENKEL AG & CO. KGAA (DE) 2022-02-03 US disclosed
CN-113710723-A Use of functionalized alpha-angelicin 汉高股份有限及两合公司 2021-11-26 CN disclosed
CN-113692404-A Functionalized alpha-angelicalactone monomers and polymers obtained therefrom 汉高股份有限及两合公司 2021-11-23 CN disclosed
WO-2020212149-A1 USE OF FUNCTIONALIZED ALPHA-ANGELICA LACTONES HENKEL AG & CO. KGAA (DE) 2020-10-22 WO disclosed
WO-2020212041-A1 FUNCTIONALIZED α-ANGELICA LACTONE MONOMERS AND POLYMERS OBTAINED THEREFROM HENKEL AG & CO. KGAA (DE) 2020-10-22 WO disclosed
EP-3725784-A1 FUNCTIONALIZED ALPHA-ANGELICA LACTONE MONOMERS AND POLYMERS OBTAINED THEREFROM Henkel AG & Co. KGaA (DE) 2020-10-21 EP disclosed
EP-3725820-A1 USE OF FUNCTIONALIZED ALPHA-ANGELICA LACTONES Henkel AG & Co. KGaA (DE) 2020-10-21 EP disclosed
US-20080220288-A1 Light-Emitting Device, And Method For The Manufacture Thereof KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) 2008-09-11 US disclosed
CN-101263617-A Light-emitting device, and method for the manufacture thereof KONINKL PHILIPS ELECTRONICS NV (NL) 2008-09-10 CN disclosed
EP-1927145-A2 LIGHT-EMITTING DEVICE, AND METHOD FOR THE MANUFACTURE THEREOF Koninklijke Philips Electronics N.V. (NL) 2008-06-04 EP disclosed
WO-2007031923-A2 LIGHT-EMITTING DEVICE, AND METHOD FOR THE MANUFACTURE THEREOF KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) 2007-03-22 WO disclosed
US-20040082549-A1 Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections JOMAA HASSAN (DE) 2004-04-29 US disclosed
US-6680308-B1 ADMINISTERING N-(FORMYL OR ACETYL)-N-HYDROXYLAMINO)-ALKYLPHOSPHONIC ACID DERIVATIVE AS VIRICIDE, PARASITICIDE OR FUNGICIDE BIOAGENCY AG (DE) 2004-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033370-A1 FUNCTIONALIZED A- ANGELICA LACTONE MONOMERS AND POLYMERS OBTAINED THEREFROM AS3MT, EBPL, ACSL6 DNM1 4157/4885THRB 4209/4885TSHR 3080/4885
US-20040082549-A1 Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections PON1, DDT, GPX1 DNM1 819/4885THRB 1366/4885TSHR 1150/4885
US-11697643-B2 Use of functionalized alpha-angelica lactones RXRA, ERGIC1, RXRB DNM1 3908/4885THRB 3436/4885TSHR 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.